Centessa Pharmaceuticals (CNTA) Receivables - Other (2024 - 2026)

Centessa Pharmaceuticals (CNTA) has 3 years of Receivables - Other data on file, last reported at $3.3 million in Q1 2026.

• Receivables - Other for Q1 2026 came in at $3.3 million, up 143.97% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.3 million (up 143.97% YoY), and the FY2025 annual result was $3.4 million, up 1070.73% from the prior year.
• Receivables - Other eased to $3.3 million in Q1 2026 per CNTA's latest filing, from $3.4 million in the prior quarter.
• Over five years, Receivables - Other peaked at $3.4 million in Q4 2025 and troughed at $287000.0 in Q4 2024.
• A 3-year average of $2.1 million and a median of $2.1 million in 2025 frame the typical range for Receivables - Other.
• The sharpest annual moves came in 2025 and 2026: Receivables - Other soared 1070.73% in 2025, then surged 143.97% in 2026.
• A 3-year view of Receivables - Other shows it stood at $287000.0 in 2024, then soared by 1070.73% to $3.4 million in 2025, then decreased by 2.41% to $3.3 million in 2026.
• Business Quant data shows CNTA's Receivables - Other at $3.3 million in Q1 2026, $3.4 million in Q4 2025, and $1.9 million in Q3 2025.